SAN FRANCISCO, March 3, 2015 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX) today announced that on March 2, 2015, the Company received the formal determination of the NASDAQ Listing Qualifications Panel indicating that the Company has satisfied all requirements for continued listing on The NASDAQ Capital Market, including the minimum $2.5 million stockholders' equity requirement. Accordingly, the hearing matter has been closed.
CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.
CONTACT: CollabRx Contacts: Thomas R. Mika President & Chief Executive Officer CollabRx, Inc. 415-248-5350 www.collabrx.com Dian Griesel Int'l. Laura Radocaj - media firstname.lastname@example.org 212-825-3210 Cheryl Schneider - investors email@example.com 212-825-3210